Recent 8-K filings for BPTH

• May 26, 2026, 2:46 PM ET other material materiality 0.75 neutral item 8.1

  Bio-Path launches AI-driven digital asset treasury, assigns up to $10M of CEO's $57.9M judgment

  Board approved Digital Asset Treasury 2.0 using AI to trade and accumulate L1/L2 blockchains; Coinbase account to be opened.

• March 20, 2026, 7:59 PM ET other material materiality 0.55 neutral item 5.03item 8.1 ◈ Governance Changes

  Bio-Path Holdings completes domestication to Wyoming, creates Series S Preferred stock

  Domestication to Wyoming approved March 5, 2026; state of incorporation changed from Delaware.

• February 24, 2026, 6:59 PM ET other material materiality 0.85 neutral item 5.01item 5.03item 7.1item 8.1

  Bio-Path issues Series S preferred to CEO entity, giving 51% voting control; cancels reverse split, plans trial restarts

  Issued 51 Series S preferred shares (1% vote each) and 2M warrants to CEO-controlled SGA, granting 51% voting control.

• November 14, 2025, 6:59 PM ET other materiality 0.70 negative item 5.02item 8.01

  Bio-Path warns of going concern doubt, seeks financing; director resigns

  Director Douglas Morris resigned effective Nov 13, 2025; resignation received Nov 4.

• October 29, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02

  Bio-Path appoints Vikram Grover as CEO, CFO and director; Morris resigns as interim CEO/CFO

  Vikram Grover elected President, CEO, CFO and Board member effective October 22, 2025.

• August 13, 2025, 7:59 PM ET other material materiality 0.65 negative item 4.01item 9.01 ◈ Auditor Changes

  Bio-Path Holdings dismisses EY as auditor; no disagreements; seeking replacement

  Board approved dismissal of EY as independent auditor on Aug 13, 2025, effective immediately.

• June 24, 2025, 7:59 PM ET other material materiality 0.95 negative item 5.02item 8.01 ◈ executive_change ×4

  Bio-Path Holdings CEO and entire board resign; operations paused, employees furloughed

  CEO/President/CFO/Chairman Peter H. Nielsen resigned June 20, 2025, from all roles.

• May 2, 2025, 7:59 PM ET other materiality 0.40 positive item 8.01item 9.01

  Bio-Path announces third pre-clinical milestone for BP1001-A in obesity/Type 2 diabetes

  BP1001-A rescues AKT activity decrease in liver cells, preventing insulin resistance.

• April 29, 2025, 7:59 PM ET debt materiality 0.60 negative item 1.01item 2.03item 3.02item 9.01 ◈ Debt Financings

  Bio-Path issues $161K promissory note to Quick Capital; default-conversion at 65% of low bid

  Principal $161K, purchase price $140K after $21K original issue discount.

• March 28, 2025, 7:59 PM ET debt materiality 0.60 negative item 1.01item 2.03item 3.02item 9.01 ◈ Debt Financings

  Bio-Path issues $100K promissory note with default conversion at 65% of bid price

  Net proceeds of $87,000 after $13,050 original issue discount; note principal $100,050.

• March 28, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Bio-Path Holdings FY2024 net loss $9.9M; cash $1.2M; clinical progress in obesity and AML

  Net loss of $9.9M ($4.12 per share) vs $16.1M ($33.63 per share) in FY2023.

• March 19, 2025, 7:59 PM ET other material materiality 0.55 positive item 7.01item 9.01

  Bio-Path pre-clinical data shows BP1001-A restores insulin sensitivity, supporting obesity/T2D potential

  BP1001-A attenuated palmitic acid-induced insulin resistance in C2C12 myoblasts and myotubes.

• March 7, 2025, 6:59 PM ET debt materiality 0.50 neutral item 1.01item 2.03item 3.02item 9.01 ◈ Debt Financings

  Bio-Path Holdings enters $161,000 promissory note financing with 1800 Diagonal Lending

  Issued $161,000 promissory note at $140,000 after $21,000 OID; 12% one-time interest.

• February 18, 2025, 6:59 PM ET other material materiality 1.00 negative item 3.01 ◈ Listing & Compliance Notices

  Nasdaq delists Bio-Path Holdings for failure to meet equity requirement

  Nasdaq notified Bio-Path on Feb 14, 2025; trading suspended at open on Feb 19, 2025.

• January 10, 2025, 6:59 PM ET other material materiality 0.55 neutral item 7.01item 9.01

  Bio-Path provides 2025 clinical update; plans IND for obesity drug, advances AML & solid tumor trials

  Prexigebersen Phase 2 AML trial: biomarker package to identify responders; expects completion of Cohort 2 & interim analysis for Cohort 3 in 2025.

• December 19, 2024, 6:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Bio-Path reports preclinical data for BP1001-A: enhanced insulin sensitivity in obesity/T2D models

  BP1001-A reduced Grb2 protein expression in myoblast cells and increased p-AKT and p-FOXO-1 in myoblast and hepatoma cells.

• December 13, 2024, 6:59 PM ET other material materiality 0.75 negative item 3.01item 5.02item 5.07item 9.01 ◈ Listing & Compliance Notices

  Bio-Path receives Nasdaq bid-price deficiency notice; shareholders OK reverse split

  Nasdaq letter Dec 12, 2024: closing bid below $1 for 30 straight days; 180 days until June 10, 2025 to comply.

• December 12, 2024, 6:59 PM ET other material materiality 0.75 neutral item 7.01item 9.01

  Bio-Path outlines obesity program for BP1001-A; discontinues BP1002 Phase 1 trial

  BP1001-A aims to treat obesity in Type 2 diabetes by downregulating Grb2 to enhance insulin signaling.

• November 25, 2024, 6:59 PM ET regulatory materiality 0.70 neutral item 8.01item 9.01

  Nasdaq panel grants Bio-Path continued listing subject to $2.5M equity compliance by Jan 31, 2025

  Company must demonstrate minimum $2.5M stockholders' equity by Jan 31, 2025 to remain listed.

• November 15, 2024, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Bio-Path Q3 net loss $2.1M; expands DNAbilize into obesity; cash $0.6M

  Net loss of $2.1M ($0.70 per share) vs $3.2M ($6.36) in Q3 2023; R&D expense down to $1.3M from $2.3M.

• October 11, 2024, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 3.02item 7.01item 9.01

  Bio-Path raises ~$4M in private placement; launches obesity drug program BP1001-A

  Gross proceeds of ~$4.0M from private placement of pre-funded warrants and series A/B warrants at $0.87 per unit; warrants exercisable at $1.00 per share.

• September 13, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 3.01

  Bio-Path receives Nasdaq delisting notice for equity non-compliance; plans appeal

  Received Nasdaq delisting letter on Sept 12, 2024 for failing to meet $2.5M stockholders' equity requirement.

• August 21, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Bio-Path reports solid tumor patient response to BP1001-A; AML patients show extended remission

  First patient at 90 mg/m2 dose of BP1001-A had 15% tumor reduction and stable disease after 6 cycles.

• August 15, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02item 9.01

  Bio-Path posts Q2 2024 net loss of $1.9M; cash position improves to $4.0M

  Net loss of $1.9M ($1.16 per share) vs $4.2M ($10.64 per share) in Q2 2023.

• July 11, 2024, 7:59 PM ET other material materiality 0.55 positive item 8.01item 9.01

  Bio-Path provides clinical update; expands prexigebersen into obesity preclinical studies

  Phase 2 AML trial paused for interim analysis; expects to complete enrollment in cohorts 1&2 over 18 months.

• June 14, 2024, 7:59 PM ET other material materiality 0.65 positive item 7.01item 9.01

  Bio-Path interim Phase 2 data: 75% CR/CRh/CRi in newly diagnosed AML with prexigebersen combo

  Cohort 1 (newly diagnosed): 15/20 evaluable patients achieved CR/CRh/CRi; median age 75, adverse-risk or secondary AML.

• June 14, 2024, 7:59 PM ET regulatory materiality 0.65 negative item 8.01

  Bio-Path gets Nasdaq extension to Sept 8 to meet $2.5M equity rule

  Non-compliance with Nasdaq minimum stockholders' equity of $2.5M noted March 12, 2024.

• June 5, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 7.01item 9.01

  Bio-Path Holdings raises $4.0M in private placement of common stock and warrants

  Gross proceeds ~$4.0M from sale of 1,809,955 shares (or equivalents) and warrants at $2.21 per unit.

• June 3, 2024, 7:59 PM ET other material materiality 0.80 positive item 8.01item 9.01

  Bio-Path presents positive Phase 2 prexigebersen data at ASCO; 75% CR/CRh/CRi in newly diagnosed AML

  Cohort 1 (newly diagnosed AML): 75% of evaluable patients (15/20) achieved CR/CRh/CRi; median age 75 yrs, adverse-risk or sAML.

• May 30, 2024, 7:59 PM ET other materiality 0.50 positive item 7.01item 9.01

  Bio-Path presents positive interim Phase 2 prexigebersen AML data at ASCO and EHA

  ASCO oral presentation on June 1, 2024 (8:00 AM CT, McCormick Place, abstract #6511).

• May 15, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Bio-Path Q1 net loss $3.2M ($4.88/sh); raises $3.5M post-quarter

  Net loss $3.2M ($4.88 EPS) vs $5.3M ($13.25 EPS) in Q1 2023; R&D expense down to $2.3M from $4.0M.

• April 19, 2024, 7:59 PM ET other material materiality 0.55 neutral item 1.01item 3.02item 8.01item 9.01 ◈ Material Agreements ×2

  Bio-Path Holdings raises $1.2M in registered direct offering and warrants

  Sold 375,000 shares at $3.225 per share for gross proceeds of $1.2 million.

• April 19, 2024, 7:59 PM ET other material materiality 0.50 neutral item 8.01item 9.01

  Bio-Path raises additional $1.1M ATM capacity after completing initial $2M sale

  Sold 436,511 shares for ~$2.0M gross proceeds under prior ATM; offering terminated April 19, 2024.

• April 18, 2024, 7:59 PM ET other material materiality 0.65 positive item 8.01item 9.01

  Bio-Path completes second dose cohort in Phase 1/1b trial of BP1002 in AML

  Second dose cohort (40 mg/m²) completed in dose escalation for refractory/relapsed AML patients, including venetoclax-resistant.

• April 15, 2024, 7:59 PM ET other material materiality 0.40 positive item 8.01item 9.01

  Bio-Path expands global patent portfolio with new patents in Mexico, Australia, Japan

  Received newly issued patents in Mexico (IGF-1R inhibition), Australia (STAT3, IGF-1R, BCL2 inhibition), and Japan (liposomal formulation).

• April 4, 2024, 7:59 PM ET other material materiality 0.40 neutral item 1.01item 9.01 ◈ Material Agreements

  Bio-Path enters ATM agreement for up to $2M common stock offering

  Entered At The Market Offering Agreement with H.C. Wainwright & Co. for up to $2.0M of common stock.

• April 2, 2024, 7:59 PM ET other material materiality 0.60 neutral item 7.01item 9.01

  Bio-Path provides 2024 clinical update: AML, solid tumor trials advancing

  Phase 2 prexigebersen trial in AML targets FDA Fast Track for fragile patients; median survival 5-10 months.

• March 27, 2024, 7:59 PM ET other material materiality 0.40 neutral item 8.01item 9.01

  Bio-Path Holdings closes $300K registered direct offering with warrants

  Sold 75,000 shares of common stock at $3.99 per share in a registered direct offering, raising ~$299,250.

• March 26, 2024, 7:59 PM ET other material materiality 0.60 neutral item 1.01item 3.02item 9.01 ◈ Material Agreements

  Bio-Path raises ~$299k in registered direct offering; issues warrants

  Gross proceeds of $299,250 from 75,000 shares at $3.99/share; net ~$0.2M after fees.

• March 13, 2024, 7:59 PM ET regulatory materiality 0.85 negative item 3.01 ◈ Listing & Compliance Notices

  Bio-Path receives Nasdaq delisting notice for failing $2.5M equity minimum

  Deficiency letter received March 12, 2024 citing non-compliance with Nasdaq Listing Rule 5550(b)(1).

• March 11, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01

  Bio-Path regains Nasdaq minimum bid price compliance; delisting risk resolved

  Received Nasdaq letter on March 8, 2024 confirming bid price compliance.

• March 8, 2024, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01 ◈ Earnings Releases

  Bio-Path Holdings FY2023 net loss $16.1M; cash drops to $1.1M from $10.4M

  Net loss $16.1M ($33.63 per share) vs $13.9M ($38.12 per share) in FY2022.

• February 23, 2024, 6:59 PM ET other material materiality 0.70 negative item 3.03item 5.03item 7.01item 9.01 ◈ Governance Changes

  Bio-Path Holdings announces 1-for-20 reverse stock split effective Feb 22, 2024

  Reverse split ratio 1-for-20 effective 5:30 p.m. ET Feb 22, 2024; trading starts split-adjusted on Nasdaq under BPTH on Feb 23.

• February 2, 2024, 6:59 PM ET other materiality 0.55 neutral item 5.07 ◈ Shareholder Votes

  Bio-Path shareholders approve reverse stock split up to 1-for-50 at special meeting

  Reverse stock split proposal approved with 3,730,379 votes for and 3,189,586 against; 42,153 abstentions.

• January 23, 2024, 6:59 PM ET other material materiality 0.50 neutral item 5.07

  Bio-Path Holdings adjourns special meeting to Jan 30 for reverse split vote

  Stockholders approved adjournment (4.05M for, 2.31M against) to solicit additional proxies.

• January 10, 2024, 6:59 PM ET other material materiality 0.65 neutral item 7.01item 9.01

  Bio-Path completes first dose cohort in Phase 1 trial of BP1002 for lymphoma/CLL

  BP1002, a liposomal Bcl-2 antisense, advanced to next dose cohort (40 mg/m²) after completing 20 mg/m² cohort safely.

• December 15, 2023, 6:59 PM ET other materiality 0.10 neutral item 5.07

  Bio-Path Holdings stockholders elect five director nominees, ratify Ernst & Young as auditor

  All five director nominees elected: Peter H. Nielsen, Heath W. Cleaver, Paul D. Aubert, Aline Sherwood, Douglas P. Morris.

• December 14, 2023, 6:59 PM ET other material materiality 0.55 positive item 7.01item 9.01

  Bio-Path completes first dose cohort of BP1002 Phase 1/1b trial in AML; no dose-limiting toxicities

  First cohort (20 mg/m2) completed with no dose-limiting toxicities in 3 evaluable refractory/relapsed AML patients.

• December 8, 2023, 6:59 PM ET other materiality 0.20 neutral item 5.03item 9.01 ◈ Governance Changes

  Bio-Path Holdings reduces stockholder meeting quorum to one-third of shares

  Board approved Amendment No. 1 to Bylaws on Dec 7, 2023, reducing quorum from majority to one-third of shares entitled to vote at stockholder meetings.

• November 15, 2023, 6:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01 ◈ Earnings Releases

  Bio-Path Q3 net loss $3.2M; positive prexigebersen AML Phase 2 data

  Net loss of $3.2M ($0.32/sh) vs $3.5M ($0.49/sh) in Q3 2022, improvement from lower expenses and warrant income.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 1.00 · Median 0.60 · Most common event other_material

12 positive 12 negative 26 neutral

source · BPTH on sec.gov